Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $65 to $28.
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $65 to $28.